Evidence map›Paper›PMID 41833512›Full record

ArticleAddiction (Abingdon, England)2026

A call for action: Closing the evidence gap in management of stimulant-induced psychosis.

Anne Bouthillier, Heidar Sharafi, Adam Bisaga, Didier Jutras-Aswad

Abstract read
In one paragraph

Article in Addiction (Abingdon, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Holistic approach to substance-induced psychosis.Addiction (Abingdon, England) · 2026
    Article
  3. Article
  4. Keeping stimulant-induced psychosis in sight.Addiction (Abingdon, England) · 2026
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Anne BouthillierDepartment of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada.
Heidar SharafiResearch Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.
Adam BisagaDepartment of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Didier Jutras-AswadDepartment of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada.ORCID https://orcid.org/0000-0002-8474-508X

Funding

CHUM Foundation
6 · The paper itself

Abstract

backgroundStimulant-induced psychosis (StIP) is emerging as one of most pressing health challenges. Over the past two decades, stimulant-related harms and psychiatric care demands have risen sharply. Individuals with StIP often present with severe agitation and high suicide risk, and up to half progress to chronic psychotic illness within two years. Despite this burden, clinical recommendations remain sparse and largely based on consensus rather than evidence. This article aims to critically appraise current conceptual and therapeutic approaches to StIP, highlight evidence gaps, and outline priorities for research and clinical practice. ARGUMENT: We propose a re-evaluation of StIP nosology, shifting away from DSM-5 distinctions that require symptom presence beyond abstinence and often fail in real-world settings. Management might require stage-specific approaches- acute (safety and short-term antipsychotics), subacute (stabilization and relapse prevention), and long-term (management of recurrent or persistent psychosis)- yet no validated staging models exist. Antipsychotic prescribing remains guided by expert opinion, with unresolved questions around choice of agent, treatment duration, and relapse prevention strategies. Evidence for psychosocial and behavioral interventions is very limited. Individualized care, supported by predictive tools, biomarkers, and longitudinal risk stratification, is essential to identify individuals at highest risk of progression and chronicity while minimizing unnecessary long-term pharmacotherapy.

conclusionsStimulant-induced psychosis (StIP) exemplifies a widening evidence-practice gap. Addressing this requires a coordinated research agenda to address nosology and phenomenology, validate diagnostic algorithms, develop stage-specific management models, and test integrated pharmacological and behavioral strategies. Without such efforts, outcomes will remain poor, and StIP will continue to represent one of psychiatry's most consequential yet neglected syndromes.

Indexed as

Central Nervous System StimulantsPsychoses, Substance-InducedAntipsychotic AgentsEvidence GapsHumansAntipsychotic AgentsCentral Nervous System Stimulantsconcurrent disordersevidence gapsguidelineintegrated therapymethamphetaminepsychotic disorders

Identifiers

PMID41833512
PMCPMC13486903

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.